To this end, we conducted a siRNA knockdown of SEMA3C (25 nM) on MCF7 and T47D cells, and 72 h post-treatment we analyzed cell signaling pathways known to be upregulated in ER+ breast cancer via immunoblotting. This evidence concerns the gene SEMA3C and breast carcinoma.